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BACKGROUND: The aims of this study were to determine which consent procedure patients prefer for use of stored tissue for research
purposes and what the effects of consent procedures on actual consenting behaviour are.
METHODS: We offered 264 cancer patients three different consent procedures: ‘one-time general consent’ (asked written informed
consent), ‘opt-out plus’ (had the opportunity to opt out by a form), or the standard hospital procedure (control group). The two
intervention groups received a specific leaflet about research with residual tissue and verbal information. The control group only
received a general hospital leaflet including opt-out information, which is the procedure currently in use. Subsequently, all patients
received a questionnaire to examine their preferences for consent procedures.
RESULTS: In all, 99% of patients consented to research with their residual tissue. In the ‘one-time consent’ group 85% sent back their
consent form. Patients preferred ‘opt-out plus’ (43%) above ‘one-time consent’ (34%) or ‘opt-out’ (16%), whereas 8% indicated that
they did not need to receive information about research with residual tissues or be given the opportunity to make a choice.
CONCLUSIONS: The ‘opt-out plus’ procedure, which places fewer demands on administrative resources than ‘one-time consent’, can
also address the information needs of patients.
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Storage of human tissue after clinical procedures is important for
two major reasons. First, the tissue can be used for future
diagnosis and treatment of the patient and, second, it is a valuable
resource for medical research (Ashburn et al, 2000; van Diest,
2002; Oosterhuis et al, 2003; Weir and Olick, 2004). Consent for
use of stored tissue for research purposes can be obtained in a
variety of ways, and there is on-going discussion about which
procedure complies best with patients’ wishes while also being
feasible in clinical practice (Maschke, 2005). Some argue that
implied consent with the opportunity to opt-out is sufficient (van
Diest, 2002; Furness, 2003; Coebergh et al, 2006; Bryant et al, 2008).
Under the condition of ‘opt-out’, information about research with
tissue is provided but patients are not actively asked to make a
decision about research with their tissue. Others claim that explicit
‘one-time general’ (for all future research) consent should be asked
(Hansson et al, 2006; Pentz et al, 2006; Wendler, 2006). An
alternative for ‘one-time general consent’ is ‘one-time specific
consent’ (providing consent for specific types of future research at
one moment) that provides opportunities to have more control
over future uses of tissue, but would stifle research (Greely, 1999;
Lauri, 2002; Caulfield et al, 2003; Furness and Nicholson, 2004;
Dickenson, 2007; Helft et al, 2007) or requires additional resources
(Wheeler et al, 2007). Still others argue that informing patients
about future research with tissue is impossible, even in basic
terms, and that consent cannot be truly ‘informed’ (Hoeyer et al,
2004).
According to the Dutch Medical Treatment Act (Van Veen et al,
2006), anonymous samples obtained during medical treatment
may be used in medical research if the patient has not objected to
this ‘secondary use’. Active consent for use of such materials is not
required and the law does not specify how patients should be
informed about secondary use of tissue. The Medical Treatment
Act does not regulate the use of coded samples. This is done by a
Code of Conduct issued by the Dutch Federation of Medical
Scientific Societies, conceived together with patient groups and the
Royal Dutch Medical Association (Federation of Medical Scientific
Societies, 2002). The need for a new law about the use of tissue for
research is currently being discussed. Although some health
attorneys argue that expressed or explicit consent should be
obtained (Gevers, 2004; Olsthoorn-Heim and Gevers, 2004), others
favour an opt-out procedure (Van Veen et al, 2006).
There are only very few published studies comparing the effects
of informed consent procedures for the use of residual tissues for
research purposes. In the international literature and in the Dutch
context, the debate focuses on two procedures; ‘one-time consent’
or ‘opt-out’, that is, should patients be actively asked to consent or
not? In earlier research of our group (Vermeulen et al, 2009a,b),
patients indicated that ‘opt-out’ would suffice if it was ascertained
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sthat patients were well informed. The respondents in these studies
suggested a procedure that was labelled ‘opt-out plus’: patients
receive verbal and written information, a special leaflet about
tissue and research, and have the option to opt-out. In this study,
‘one-time consent’ and ‘opt-out plus’ were compared with the ‘opt-
out’ procedure currently in use in the Netherlands to determine
which consent procedure patients prefer for use of stored tissue for
research purposes and what the effects of consent procedures on
actual consenting behaviour are. The preference of patients for a
specific consent procedure was evaluated through a follow-up
survey and interviews.
MATERIALS AND METHODS
The study was performed at the Netherlands Cancer Institute–
Antoni van Leeuwenhoek Hospital (NKI–AVL) from August 2007
until January 2008. The NKI–AVL is a specialised cancer
treatment hospital with a relatively small number of beds (180)
and a large outpatient clinic.
All patients who were younger than 75 years of age who had
undergone primary surgery for breast, prostate or colorectal
cancer (three of the major cancer types treated in the NKI–AVL)
and were scheduled for an appointment within the time frame
of the study, were selected from the hospital registry (n¼277).
We selected patients younger than 75 years because of the extra
information load for the patients related to the research. Eligible
patients who had a scheduled appointment at the outpatient clinic
6 months post-surgery, a standard follow-up appointment at the
NKI–AVL for the selected tumour types, were randomly assigned
to either the ‘one-time consent’ procedure or the ‘opt-out plus’
procedure (Figure 1) (n¼146). The remaining patients, who had
either surgery more recently or surgery planned later during the
study period, were assigned to the control group (n¼131). In this
way patients were randomly assigned to the control group, based
on the timing of surgery during the study period. We chose to offer
the intervention post-surgically so as to avoid burdening patients
during early diagnosis or early treatment phase with such
additional information.
Patients who were assigned to one of the intervention arms were
asked whether they consented to the intervention taking place
during the outpatient clinic visit. The two consent procedures were
offered in blocks, 10 patients of each of the three diagnostic groups
were offered the ‘opt-out plus’ procedure, then 10 patients were
offered the ‘one-time consent’ procedure.
In the two intervention groups, patients received brief verbal
information in person from their nurse practitioner or physician,
and a leaflet about the use of stored tissue, which was specifically
written for this study. For the ‘one-time consent’ group, this verbal
information was: ‘tissue that was excised during your surgery is
stored in this hospital for future diagnosis or treatment. This tissue
may also be used in medical research, but this requires your
consent. Please read this leaflet at home and send back the consent
form within 1 month in the stamped return envelope indicating
whether you consent to the use of your tissue for future medical
research.’ For the ‘opt-out plus’ group, the verbal information
provided was; ‘tissue that was excised during your surgery is
stored in this hospital for future diagnosis or treatment. This tissue
may also be used in medical research. Please read this leaflet at
home. You may want to object to research with your tissue and you
may do so by sending back the form in the stamped return
envelope.’ The special leaflets were four pages in length and
contained paragraphs on storage and use of tissue in future
research. Information about incidental findings and contact details
in case of further questions was also included. The leaflets for the
two intervention groups differed in wording ‘consent’ vs ‘opt-out’.
The interventions were observed by one of the authors (EV).
Patients received, together with the leaflet and the consent or opt-
out form, a return envelop, which was addressed to the research
team in the hospital. Patients who did not return the form were not
sent a specific reminder but reminders were sent for the
questionnaires.
Not included in intervention:    n = 9
Refused consent for intervention:     n = 2
No contact advised by staff:             n = 2
Appointment cancelled:                     n = 2
Missed inclusion:                     n = 1
Did not speak Dutch well enough:    n = 2
277 patients with primary surgery for breast, prostate or colorectal cancer
Intervention arm:
‘’One time consent procedure’’ n = 69
Questionnaires sent to:  n = 131 patients Questionnaires sent to: n = 60 patients
Completed questionnaire: n = 68 (93%)
Interviews:           n = 37 (51%)
Completed questionnaires: n = 56 (93%)
Interviews:             n = 31 (52%)
Intervention arm:
“Opt-out plus’’ n = 77
Not included in intervention:    n = 4
No contact advised by staff:           n = 1
Appointment cancelled:                 n = 1
Missed inclusion:                           n = 2
Questionnaires sent to: n = 73 patients
n=146 with a 6-month appointment after surgery within study period;
randomised over two intervention arms
n = 131 with either surgery more recently or
surgery planned later during the study period
Completed questionnaires: n = 115 (88%)
Interviews:             n = 62   (47%)
Control group:
‘’Standard procedure’’ (‘’opt-out’’) n = 131
Figure 1 Study diagram: study groups, inclusion and response rates (questionnaires and interviews).
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sThe control group had received a general hospital leaflet
according to the standard hospital procedures, which includes
the general hospital leaflet of the NKI–AVL that informs patients,
among others, about the possible use of stored tissues for research
purposes. The text devoted to research with residual tissue in this
leaflet is 170 words in length. It states that ‘residual tissue is
sometimes used, as is the patients’ medical data, in anonymous
and coded research. Patients are informed that they can opt-out if
they wish by informing their physician, who will then make a note
in the medical charts.’ This information policy is in line with Dutch
law and comparable to that of other academic hospitals in the
Netherlands.
A questionnaire was mailed to the patients in the intervention
groups 4 weeks after the intervention took place. The patients in
the standard procedure control group were sent a similar
questionnaire 6 weeks post-surgery. The questionnaire was sent
6 weeks post-surgically because this would resemble the informa-
tion time frame of the intervention patients while creating still
somewhat more distance from the moment of diagnosis and
surgical treatment. One month after the questionnaires had been
mailed, non-respondents received a reminder. Patients who did
not respond after the reminder were contacted by phone after 1
month.
The questionnaire covered a range of topics, including: reasons
for (not) consenting, attitudes toward having been given the choice
about tissue use, the perceived usefulness of the information
provided in the leaflet, opinions about the best procedure for
informing patients and for requesting consent from patients, and
attitudes towards genetic and commercial research, tissue storage
and ownership of tissue.
The question about the various consent procedures was
introduced by text explaining that one-time general consent is a
model in which the patient is informed and actively asked
for written permission for all future research with archived
tissue. Opt-out was described as the model in which the patient is
not actively informed and not actively asked for consent;
information about research with tissue is available in the general
leaflet of the hospital and the patient can opt-out if (s)he so
chooses. ‘Opt-out plus’ was described as the model in which
patients are actively informed and offered the choice whether to
opt-out of future research with their tissue. We also asked if
patients would prefer repeated ‘fresh’ consent for specified
research projects.
All patients were also asked to participate in a telephone
interview. During these interviews a subset of questions from the
written questionnaire was discussed in-depth, with particular
emphasis placed on the questions about consent procedures, how
patients perceived the storage and use of tissue, and types of
research for which patients wished to give consent. If the
respondent agreed, the interviews were audio recorded and
subsequently transcribed. The study was approved by the
hospital’s institutional review board.
Statistical analysis
Analyses were performed to determine the consent rates by
consent procedure (based on the returned consent and opt-out
forms), to compare the baseline characteristics of the three groups,
and to compare the preference for and appreciation of the
procedures (information obtained by questionnaire and interview)
between the three groups (two intervention groups and the control
group) and between subgroups formed on the basis of tumour
type, gender, and educational level. Pearson’s w
2-test was used to
evaluate the significance of the differences. Significant predictors
of preferences observed in logistic regression models at the
univariate level were subsequently included in a multinomial
logistic regression model. All statistical tests were two-sided, with
a P-value of 0.05 or lower indicating statistical significance.
The statistical software package SPSS 15.0 (SPSS Inc., Chicago, IL,
USA) was used.
RESULTS
Patient characteristics
Of the 146 eligible patients with primary surgery for breast,
prostate or colorectal cancer, identified for block randomisation
over the intervention groups, 133 (91%) were either given the ‘one-
time consent’ procedure (n¼60, 45%) or the ‘opt-out plus’
procedure (n¼73, 55%) (Figure 1). Figure 1 shows that some
patients could not be included in the study, for example, because
they refused consent for the intervention or because the nurse
practitioners advised not to approach him/her for the study
because they considered the patient to have too much disease-
related stress. Questionnaires were obtained from 56 patients
(93%) in the ‘one-time consent’ group and 68 (93%) in the ‘opt-out
plus’ intervention (Figure 1). From the 131 patients included in the
control group, 115 (88%) questionnaires were obtained. In total,
we obtained 239 of 277 (86%) questionnaires and 130 (47%)
patients consented to an interview. Characteristics of patients in
the three groups are shown in Table 1. Women were under-
represented in the opt-out plus group compared with the other
groups (P¼0.01). Distributions of age, sex and type of cancer were
not significantly different between respondents and non-respon-
dents (data not shown).
Consent
Fifty-one consent forms (85%) were received from the 60 patients
in the ‘one-time consent’ group. Most of these consent forms
(n¼45, 88%) were returned within 1 month after the interven-
tion. None of the patients in the intervention groups withheld
consent through the consent or ‘opt-out’ form. Though of the 73
patients randomised to the ‘opt-out plus’ intervention, two (3%)
returned the ‘opt-out form’, during the interview it became clear
that neither of these two patients was actually opposed to research
with their tissue, but rather had misunderstood the directions
regarding return of the form. Two respondents, one from the ‘one-
time consent’ intervention and one from the ‘control group’,
indicated in the follow-up questionnaire that they had actually
wished to withhold consent for the use of tissue. Of all
respondents, seven indicated in the questionnaire that they did
not know whether they would want to ‘opt-out’.
The follow-up questionnaires and interviews showed that the
primary reason for respondents to provide consent was a desire to
contribute to improving treatment for future patients. Many
respondents also stated that they expected that they or their
relatives might personally benefit from future research that used
their tissue.
Appreciation of information
The majority of respondents (82 and 65% in the ‘one-time consent’
and ‘opt-out plus’ group, respectively) expressed appreciation at
being informed about research with remaining tissue (Table 2). A
minority of respondents felt that they were not well informed, but
that they wished they had been informed (Table 2). Respondents in
the ‘one-time consent’ group expressed more appreciation for the
way they were informed by the hospital than respondents in the
‘opt-out plus’ group or the ‘control group’ (Table 2). Appreciation
of information was not associated significantly with patients’ age,
sex, educational level or diagnosis (data not shown). Of the
respondents in the control group, 73% had not seen or did not
remember having read the information about tissue and research
in the general hospital leaflet. Providing information to patients in
A trial of consent procedures
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sthe two intervention groups took little time (approximately 1min).
Patients rarely asked questions about tissue and research (in later
contacts with staff members).
Preferences for consent procedures
Based on all groups combined, 43% of respondents preferred ‘opt-
out plus’, 16% ‘opt-out’, 34% ‘one-time consent’, and 8% ‘no
information at all’ (Table 3). The majority of respondents
preferred information to be given before or during hospitalisation
(Table 3). Preferences for the various consent procedures did not
differ as a function of the intervention group.
Based on the univariate analyses, preference for a regimen
varied significantly as a function of age, sex, educational level and
ownership feelings (that is, the respondent felt that the stored
residual tissue was still a part of him/herself after removal).
Respondents who were younger, female, more highly educated and
considered themselves owner of their tissue or the DNA in their
tissue, were significantly more likely to prefer the ‘one-time
consent’ and ‘opt-out plus’ procedures to ‘opt-out’. In all
subgroups, the ‘opt-out plus’ procedure was preferred more often
than the other consent procedures (Table 4).
In the multinomial logistic regression analysis, education
and ownership attitudes remained significant predictors of
preference for ‘opt-out plus’ to ‘opt out’ (Table 5). These two
factors did not explain preference for ‘one-time consent’ compared
with ‘opt-out plus’.
Expectations of patients regarding the use of residual
tissues in research
Most respondents (98%) trusted (hospital) regulations and
the protection of privacy (82%), but many (49%) were opposed
to the use of their residual tissues in ‘commercial research’. Those
who were opposed to the use of their tissue in ‘commercial
research’ tended to be more highly educated than those who
had no such objections (P¼0.008). During the interviews,
many respondents stressed the need for research results to become
available for the benefit of future patients; they considered use
of tissues by commercial parties as not contributing to the
common good.
On the basis of a feeling of reciprocity, the majority of
respondents (72%) expected to be informed about research
findings based on the use of their tissue. This typically reflected
Table 2 Study groups and appreciation of information
One-time
consent
study
group
Opt-out
plus study
group
Control
study
group
Appreciation of information *P-value¼0.00
I was well informed (n¼114, 51%) 82% 65% 27%
Information was neither good nor bad
(n¼68, 31%)
15% 29% 40%
I was poorly informed (n¼41, 18%) 4% 6% 33%
*Differences tested between the three study groups.
Table 3 Preferences regarding consent procedure for research use of
residual tissue
All respondents
(n¼239)
Type of consent procedure
‘One-time consent’ is the appropriate consent procedure 81 (34%)
‘Opt-out plus’ is the appropriate consent procedure 103 (43%)
‘Opt-out’ is the appropriate consent procedure 37 (16%)
No information needs to be provided 18 (8%)
When should information be provided?
I think it should be given before or at intake 93 (39%)
I think it should be provided during the hospital stay 50 (21%)
I think it should be provided after the hospital stay 69 (29%)
I think it should be offered otherwise 28 (11%)
How should written information be provided?
In a general hospital leaflet 100 (42%)
In a specific leaflet about residual tissue and research 119 (50%)
I think no information should be provided 12 (5%)
Information should be provided otherwise 6 (3%)
Table 1 Characteristics of respondents of the questionnaires in the three study groups
One-time consent
study group (n¼56)
Opt-out plus
study group (n¼68)
Control study
group (n¼115)
All respondents
(n¼239)
Non response
(n¼38)
Age (at time of study) *P-value¼0.14
o50 years 11 (20%) 9 (13%) 30 (26%) 50 (21%) 12 (32%)
50–64 years 29 (52%) 40 (59%) 65 (57%) 134 (56%) 16 (42%)
65–75 years 16 (29%) 19 (28%) 20 (17%) 55 (23%) 10 (26%)
Sex *P-value¼0.01
Female 28 (50%) 29 (43%) 74 (64%) 131 (55%) 18 (47%)
Male 28 (50%) 39 (57%) 41 (36%) 108 (45%) 20 (53%)
Cancer diagnosis *P-value¼0.06
Breast cancer 21 (38%) 20 (29%) 57 (50%) 98 (41%) 15 (40%)
Prostate cancer 18 (32%) 27 (40%) 26 (23%) 71 (30%) 10 (26%)
Colorectal cancer (female) 7 (12%) 9 (13%) 17 (15%) 33 (14%) 4 (10%)
Colorectal cancer (male) 10 (18%) 12 (18%) 15 (13%) 37 (15%) 9 (24%)
Educational level (a) *P-value¼0.28
Low 13 (23%) 7 (10%) 20 (17%) 40 (17%) NA
Intermediate 21 (38%) 36 (53%) 56 (49%) 113 (47%) NA
High 22 (39%) 25 (37%) 39 (34%) 86 (36%) NA
(a) Low level education: primary school, lower vocational training or lower general training; intermediate level: intermediate vocational or intermediate/higher general; high level:
higher vocational or university training. *Differences tested between the three study groups.
A trial of consent procedures
E Vermeulen et al
1508
British Journal of Cancer (2009) 101(9), 1505–1512 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
san interest in science in general, but for some it was a desire to be
able to check the type of research for which their tissue had
been used. Most respondents (91%) also wanted to be informed
about any incidental findings that might be relevant to their
treatment.
DISCUSSION
To our knowledge, this study is the first to compare different
consent procedures for research with residual tissue. We examined
the effects of three different procedures on consent rates and
patients’ attitudes. Nearly all patients (99%) consented to research
with residual tissue. We did not find higher rates of withdrawal of
consent as a result of specific consent regimens. Of the patients in
the ‘one-time consent’ group, most returned the consent form as
requested. Patients were significantly more satisfied with the way
information was provided about research with residual tissues in
the ‘one-time consent’ and ‘opt-out plus’ groups, compared with
the control group. In the follow-up questionnaire, patients
preferred ‘opt-out plus’ above ‘one-time consent’ or ‘opt-out’
without actively being informed. Younger, more highly educated
patients and patients who believed that they ‘owned’ their tissue
were significantly more likely to prefer ‘one-time consent’ above
‘opt-out’, but not above ‘opt-out plus’.
Studies in other settings have reported similarly high consent
rates for the use of residual tissue in medical research (Hamajima
et al, 1998; Malone et al, 2002; Stegmayr and Asplund, 2002; Jack
and Womack, 2003; Furness and Nicholson, 2004; Chen et al, 2005;
Wheeler et al, 2007; Bryant et al, 2008). Our results show that
patients prefer to be informed about research with tissue, refuting
authors who argue that patients do not need to be informed and do
not need to be provided with the opportunity to opt-out or
withhold consent for future research with residual tissue (Keulartz
et al, 2004; Swierstra, 2004). Respondents felt respected and valued
by being informed, but most felt that actually giving consent was of
secondary importance (66% did not prefer ‘one-time consent’), as
was also observed by Hamilton et al (2007) and previous studies
of our own group (Vermeulen et al, 2009a, b). The consent
procedure that was offered to patients in the ‘one-time consent’
and ‘opt-out plus’ groups involved the reading of several pages of
information in the leaflet and we asked the patient to read this
leaflet at home.
We considered it undesirable to ask patients to read the
information and make a decision about consent or opt-out
concerning research with tissue immediately during the consulta-
tion with the staff member. According to national and interna-
tional ethical guidelines, patients should have several days to
consider their decision to sign a consent form or not. It is possible
that some patients would prefer to make a decision during the
consultation (though none of the patients specifically indicated
this). In such a scenario patient preferences could differ from our
findings and such an ‘in-person’ procedure would eliminate part of
the additional work required for the one-time consent compared
with the opt-out-plus procedure. Some patients indicated in the
interview that they deemed the additional paper administration of
Table 4 Predictors of preference for different consent procedure
Preference reported in the questionnaire
Prefer one-time consent Prefer opt-out plus Prefer opt-out Information not needed P-value**
Study group 0.53
One-time consent (n¼56) 38%* 45%* 9%* 9%*
Opt-out plus (n¼68) 35% 37% 18% 10%
Control group (n¼115) 31% 46% 17% 5%
Age (at time of study) 0.008
o50 years (n¼50) 40% 40% 18% 2%
50–64 year (n¼134) 37% 45% 13% 5%
65–75 years (n¼55) 20% 42% 20% 18%
Sex 0.46
Female (n¼131) 38% 41% 14% 7%
Male (n¼108) 29% 45% 18% 8%
Cancer diagnosis 0.86
Breast cancer (n¼98) 39% 42% 13% 6%
Prostate cancer (n¼71) 32% 44% 16% 9%
Colorectal cancer (n¼70) 29% 44% 19% 9%
Educational level (a) 0.01
Low (n¼40) 20% 35% 28% 18%
Intermediate (n¼113) 35% 43% 15% 7%
High (n¼86) 38% 48% 11% 4%
Do you consider yourself the owner of stored tissue? 0.039
No (n¼144, 62%) 29% 42% 20% 9%
Yes (n¼87, 38% ) 41% 45% 8% 6%
Do you consider yourself the owner of DNA in stored tissue? 0.006
No (n¼111, 47%) 32% 37% 19% 12%
Yes (n¼98, 43%) 36% 53% 7% 4%
(a) Low level education: primary school, lower vocational training or lower general training; intermediate level: intermediate vocational or intermediate/higher general; high level:
higher vocational or university training. *Row percentages count to 100. **Differences tested between the four preferences reported in the questionnaire.
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sthe informed consent procedure unnecessary. However, none
declared that this was the main reason for preferring the opt-out
plus above the informed consent procedure.
Several authors have argued that implied consent with ‘opt-out’
suffices (van Diest, 2002; Coebergh et al, 2006; Johnsson et al,
2008a); they fear that a ‘one-time consent’ regimen would delay
or inhibit research or that the informed consent process would
itself cause selection bias (Junghans et al, 2005; Halamka, 2006;
Watson, 2006). The report of the Dutch Royal Academy of Sciences
(Royal Dutch Academy of Sciences. Foresight Committee on
Multifactorial Diseases in the Genomics Age, 2006) also advised
‘opt-out’, largely based upon concerns that obtaining ‘one-time
general consent’ would involve a great deal of effort from health-
care workers, and that nonetheless a substantial non-response
would result, which would create a bias in the tissue collections
available for research (Junghans et al, 2005; Helft et al, 2007).
We observed no negative effect of the interventions in the sense
that more patients withheld consent. However, only 85% of
patients asked for ‘one-time consent’ returned the consent
form (without a reminder). This implies that the model of ‘one-
time consent’ would cost considerable effort from the hospital to
obtain higher response rates. We found that a brief verbal
explanation by the nurse practitioners or physician of the ‘opt-
out plus’ procedure was feasible and appreciated by patients. This
was also suggested by others (Axler et al, 2008; Johnsson et al,
2008b; Hewitt et al, 2009). Others found indications that less
privileged groups might be more reluctant to research with tissue
(Helft et al, 2007) and may want to be asked for consent in a
stricter procedure. We think, however, that the opt-out plus
procedure is also strict seen from the patients’ perspective; the
patient is as fully informed as in the one-time consent procedure
and is facilitated to make a decision. We think therefore that opt-
out plus could also be a suitable procedure in populations or
countries less trusting. However, when obtaining samples ex-
plicitly for research purposes only, explicit consent of patients is
required (also according to Dutch law).
When interpreting the results of our study, its strengths and
limitations should be considered. The study groups were relatively
small and only few patients withheld the consent, which did not
allow subgroup analysis of decliners. Our study population was
restricted to cancer patients diagnosed before the age of 76 years
who were treated in a specialised cancer hospital. Thus, it is
possible that the observed preferences for the three consent
regimens might be different in (non-) cancer patient populations
treated in general, community hospitals. Older and less educated
patients more often preferred regimens without active provision of
information. As the cancer patients treated in our hospital tend to
be somewhat younger and more highly educated than those treated
in community hospitals, one might expect that, in other treatment
settings, even more patients would prefer the ‘opt-out plus’
procedure.
We have not measured how strong patients’ opinions for a
specific consent procedure were. As most patients stressed the
importance of informing patients, we think that this is the most
important element of the procedure. We suppose that patients who
feel that they want to be asked for explicit consent can see this
procedure as a means of asking consent, while others who do not
care about their residual tissue, can easily put the information
aside.
Patients in our study considered their tissue to be special, as it
allows them to contribute to medical progress. Few empirical data
exist describing the attitudes of cancer patients towards residual
tissue storage and use in research (Kaphingst et al, 2006). Earlier
studies found that surgically resected tissue had no special
emotional value for most respondents (Start et al, 1996; Medical
Research Council, 2000). However, a sizeable minority (38%) of
our respondents considered themselves to be owners of residual
tissue. In other research only 10% (Start et al, 1996) or 23%
(Bryant et al, 2008) of patients stated that they believed
they retained ownership over tissue removed at surgery. However,
our respondents did not interpret ‘ownership’ legally. They
considered the tissue to be theirs, but they did not feel they
should derive rights from research with their tissue. Many patients
expected to be informed about research findings based on the
use of their tissue in research. How this should or could be done
is an important issue because it is associated with a positive
attitude of patients towards research (Kaufman et al, 2008). The
respondents felt it was important that residual tissues be used
for the common good; for many this meant they did not want to
donate tissues for all future uses. In particular, ‘commercial use’
raised questions, and many respondents preferred that their
tissue should not be used commercially. Some studies report
wariness about ‘commercial use’ while other studies do not
(Jack and Womack, 2003; Treweek et al, 2009). Commercial use
may deserve more attention in regulatory aspects and informa-
tion to patients, because a large part of research is taking place in
an environment in which ‘commercial parties’ are involved. A
good understanding of patients may be crucial for patient
cooperation.
In conclusion, our results suggest that cancer patients prefer
an ‘opt-out plus’ procedure for consenting to medical research
with residual tissue. This includes both a brief, verbal explanation
and written materials that can be read at home. This approach
represents a feasible, intermediate procedure between ‘opt-out’,
which leaves many patients uninformed, and ‘one-time general
consent’, which burdens hospital staff and may create bias in tissue
collections. We think that this procedure may unify two moral
principles stressed by our respondents: that patients are informed
Table 5 Predictors of preference for one-time consent or opt-out using
opt-out plus as a reference category in a multivariate model using
multinomial logistic regression
HR (95% CI) P-value
One-time general consent
a
Age
o50 1.77 (0.65–4.86) NS
50–65 1.68 (0.71–3.94) NS
460 Ref
Educational level
Low 0.73 (0.24–2.22) NS
Intermediate 0.97 (0.50–1.88) NS
High Ref
Do you consider yourself owner of residual tissue?
No 0.64 (0.34–1.22) NS
Yes Ref
Opt-out
a
Age
o50 1.73 (0.51–5.89) NS
50–65 0.65 (0.23–1.86) NS
465 Ref
Educational level
Low 4.70 (1.44–15.39) 0.01
Intermediate 1.54 (0.56–4.26) NS
High Ref
Do you consider yourself the owner of residual tissue?
No 3.60 (1.30–9.97) 0.01
Yes Ref
aOpt-out plus¼reference category.
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sand that medical research can progress without unnecessary
hindrance.
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